MedTrace Logo

Isokinetic Strengthening of Hip Muscles Effect on Pelvic Floor Muscles Function in Females With SUI

NCT06835309 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-19

No results posted yet for this study

Summary

This study will be conducted to investigate the impact of isokinetic strengthening of hip muscles on pelvic floor muscles function in women experiencing stress urinary incontinence Does isokinetic strengthening of hip muscles impact pelvic floor muscles function in women experiencing stress urinary incontinence?

Conditions

  • Isokinetic Strengthening
  • Pelvic Floor Muscles
  • Stress Urinary Incontinence (SUI)

Interventions

OTHER

Pelvic floor muscles exercises

The exercises for strengthening the PFM were 10 contractions of 5 seconds, 15 contractions of 3 seconds, 20 contractions of 2 seconds, 20 contractions of 1 second (equal rest time between contractions), and 5 repetitions of maximum contractions while coughing (1-minute interval).25 The level of difficulty of the exercises throughout the 20 sessions was determined by the patient's position, starting in a supine position, then progressing to a sitting position and, finally, to a standing position

OTHER

Pelvic floor muscles exercises and isokinetic strengthening of hip muscles

The hip muscle strengthening exercise was executed on Biodex multi-joint system isokinetic dynamometer. Muscle tension of the lower limbs was relieved by executing 5-minute warm-up exercises using a cycle ergometer before execution of the isokinetic exercise For each hip muscle group, eight repetitions per set for 4 sets were carried out for a single exercise with a 30 second break between each set. The patient's position were the same positions used in the testing procedure. The exercises were carried out 3 times a week and the hip muscles strength evaluation was conducted after the end of the program intervention

Sponsors & Collaborators

  • British University In Egypt

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-23
Primary Completion
2025-04-23
Completion
2025-05-23

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06835309 on ClinicalTrials.gov